Forge Bi­o­log­ics bags $120M round as it looks to scale AAV man­u­fac­tur­ing for Krabbe dis­ease treat­ment

In less than a year, Forge Bi­o­log­ics has grown its staff size from just four em­ploy­ees to more than 75, a sure sign of rapid growth from the Chris Garabe­di­an-launched start up. Here’s an­oth­er sign: the $120 mil­lion Se­ries B fi­nanc­ing round the com­pa­ny just an­nounced.

The gene ther­a­py CD­MO se­cured fund­ing from RA Cap­i­tal Man­age­ment, and par­tic­i­pa­tion from Per­cep­tive Ad­vi­sors, Sur­vey­or Cap­i­tal, Oc­ta­gon Cap­i­tal and Mar­shall Wace.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER